Scarica l'app Stockscreener
71.28
0.68%
-0.49
Dopo l'orario di chiusura:
71.80
0.52
+0.73%
Precedente Chiudi:
$71.77
Aprire:
$72.2
Volume 24 ore:
454.77K
Relative Volume:
0.80
Capitalizzazione di mercato:
$3.95B
Reddito:
$76.81M
Utile/perdita netta:
$-162.42M
Rapporto P/E:
-23.84
EPS:
-2.99
Flusso di cassa netto:
$-122.49M
1 W Prestazione:
-3.78%
1M Prestazione:
+4.44%
6M Prestazione:
+11.81%
1 anno Prestazione:
+7.25%
Intervallo 1D:
$70.94
$73.33
Intervallo di 1 settimana:
$69.00
$74.73
Portata 52W:
$47.86
$107.37
Arcellx Inc Stock (ACLX) Company Profile
Nome
Arcellx Inc
Settore
Industria
Telefono
240-327-0603
Indirizzo
800 BRIDGE PARKWAY, REDWOOD CITY
Confronta ACLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
71.28 | 3.98B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Redburn Atlantic | Buy |
| 2024-09-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-03-07 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-04 | Reiterato | Needham | Buy |
| 2023-12-19 | Iniziato | Scotiabank | Sector Outperform |
| 2023-10-30 | Iniziato | TD Cowen | Outperform |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-05-18 | Iniziato | Truist | Buy |
| 2023-04-14 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-14 | Iniziato | Stifel | Buy |
| 2023-02-13 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-13 | Ripresa | BofA Securities | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-27 | Iniziato | Needham | Buy |
| 2022-07-20 | Iniziato | Canaccord Genuity | Buy |
| 2022-03-01 | Iniziato | BofA Securities | Buy |
| 2022-03-01 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Arcellx Inc Borsa (ACLX) Ultime notizie
Traders Watching For Reversal Pattern in Arcellx Inc.2025 Price Action Summary & Advanced Technical Signal Analysis - 선데이타임즈
Watch for Bullish Crossover in Arcellx Inc.Options Play & AI Enhanced Market Trend Forecasts - beatles.ru
Tick level data insight on Arcellx Inc. volatilityWeekly Gains Report & Capital Efficient Trade Techniques - Newser
Has Arcellx Inc. formed a bullish divergenceJuly 2025 Trends & Safe Capital Growth Tips - Newser
Long term hold vs stop loss in Arcellx Inc.2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How Arcellx Inc. stock performs during market volatilityEarnings Overview Report & Expert Approved Momentum Ideas - Newser
Pattern recognition hints at Arcellx Inc. upsideWeekly Investment Report & Verified Momentum Watchlists - Newser
Combining price and volume data for Arcellx Inc.Market Growth Review & Pattern Based Trade Signal System - Newser
Do Higher Losses at Arcellx (ACLX) Reflect a Strategic Shift or Growing Pains? - simplywall.st
Financial Analysis: Arcellx (NASDAQ:ACLX) and Astria Therapeutics (NASDAQ:ATXS) - Defense World
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Backtesting results for Arcellx Inc. trading strategies2025 Buyback Activity & Expert Curated Trade Setup Alerts - Newser
Real time scanner hits for Arcellx Inc. explainedQuarterly Risk Review & Daily Price Action Insights - Newser
Will Arcellx Inc. stock go up soon2025 Fundamental Recap & Technical Buy Zone Confirmations - Newser
Is Arcellx Inc. stock a buy or sellPortfolio Profit Report & Stepwise Trade Signal Guides - thegnnews.com
Heatmap analysis for Arcellx Inc. and competitorsMarket Activity Recap & Free Weekly Chart Analysis and Trade Guides - Newser
Is Arcellx Inc. a candidate for recovery play2025 Risk Factors & Weekly Watchlist for Consistent Profits - Newser
Historical volatility pattern of Arcellx Inc. visualized2025 Earnings Impact & Free Technical Pattern Based Buy Signals - Newser
Is Now a Good Time to Reenter Arcellx Inc.Risk Management & Low Risk Investment Opportunities - 선데이타임즈
Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs - MSN
Widening Losses in Q2 and H1 Might Change the Case for Investing in Arcellx (ACLX) - simplywall.st
Applying big data sentiment scoring on Arcellx Inc.Free Daily Picks With Predictable Performance - Newser
Smart tools for monitoring Arcellx Inc.’s price actionFree Chart Driven High Reward Trading Setup - Newser
Is this a good reentry point in Arcellx Inc.Future Growth Stock Forecasting Strategy - Newser
Evercore Maintains Arcellx(ACLX.US) With Buy Rating, Maintains Target Price $115 - 富途牛牛
Evercore ISI Maintains Buy Rating on Arcellx Inc with $115 Price Target - AInvest
Why Arcellx Inc. stock attracts strong analyst attentionDaily Upside Movement Prediction With Data - Newser
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Can you recover from losses in Arcellx Inc.Free Risk Managed Intraday Trade Alerts - Newser
Analysts Have Lowered Expectations For Arcellx, Inc. (NASDAQ:ACLX) After Its Latest Results - simplywall.st
We Think Arcellx (NASDAQ:ACLX) Can Afford To Drive Business Growth - Yahoo Finance
A Quick Look at Today's Ratings for Arcellx(ACLX.US), With a Forecast Between $105 to $134 - 富途牛牛
Canaccord Genuity Sticks to Its Buy Rating for Arcellx Inc (ACLX) - The Globe and Mail
Using Ichimoku Cloud for Arcellx Inc. technicalsOversold Opportunity Scanner with RSI Data - Newser
Using Bollinger Bands to evaluate Arcellx Inc.Near-Term Market Opportunity Forecast Sheet - Newser
Published on: 2025-08-08 23:14:52 - Newser
Arcellx Inc. stock volume spike explainedLoss Limitation Strategy Based on Analysis - Newser
Did Widening Losses and Falling Sales Just Shift Arcellx's (ACLX) Investment Narrative? - simplywall.st
Arcellx 2025 Q2 Earnings Deepened Losses Amid Declining Revenue - AInvest
Does Arcellx Inc. have a sustainable dividendShort-Term Explosive Growth - thegnnews.com
Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating - TipRanks
Arcellx shares rise 3.32% intraday after reporting positive Q2 2025 financial results and potential life-changing therapy for multiple myeloma patients. - AInvest
Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Promising Outlook for Arcellx Inc.: Buy Rating Backed by Strong Anito-cel Therapy Performance and Favorable Safety Profile - TipRanks
Arcellx earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Arcellx Inc: Promising Developments and Strong Clinical Data Drive Buy Rating - TipRanks
Arcellx Inc Shares Dip Amid Revenue Concerns - TipRanks
Arcellx reports Q2 EPS (94c), consensus ($1.03) - TipRanks
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Arcellx Q2 Revenue Misses Estimates, Adjusted EPS Beats Consensus - AInvest
Earnings Flash (ACLX) Arcellx, Inc. Reports Q2 Revenue $7.6M, vs. FactSet Est of $13.5M - MarketScreener
Arcellx Inc Azioni (ACLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arcellx Inc Azioni (ACLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Patel Kavita | Director |
Jun 10 '25 |
Sale |
67.36 |
1,500 |
101,040 |
0 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):